Study 435Summary

• Efficacy

  • Change in HBV DNA and ALT similar to pivotal studies
  • Normalization of albumin, bilirubin, and prothrombin time
  • Stabilization or improvement in CPT Score
  • No adefovir-associated resistance mutations identified through 48 weeks (n=55)

• Safety

  • Safety profile consistent with advanced liver disease and co-morbidities
  • Renal function should be monitored closely before and during therapy

Previous slide

Next slide

Back to first slide

View graphic version